Relationships between bladder dose–volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer

Carillo, V.; Cozzarini, C.; Rancati, T.; Avuzzi, B.; Botti, A.; Borca, Valeria Casanova; Cattari, G.; Civardi, Francesco; Esposti, C. Degli; Franco, Pierfrancesco; Girelli, G.; Maggio, A.; Muraglia, A.; Palombarini, M.; Pierelli, A.; Pignoli, E.; Vavassori, V.; Zeverino, M.; Valdagni, Riccardo; Fiorino, Claudio

doi:10.1016/j.radonc.2014.02.006

Cited by 45 publications

(23 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apart from the dosimetric factors [3][4][5][6], urinary symptoms have been demonstrated to be influenced by other comorbidities, including hypertension [7,8], diabetes [9,10] and baseline urinary symptoms [11,12]. There are suggestions that the intake of certain medications related has an impact on the interaction between radiation treatment and biological systems, which influences the expression of symptoms [10,13].…”

Section: Introductionmentioning

confidence: 99%

“…There are suggestions that the intake of certain medications related has an impact on the interaction between radiation treatment and biological systems, which influences the expression of symptoms [10,13]. Anti-hypertensive medication [5] and anticoagulants [10] were associated with a higher risk of acute and late urinary symptoms, respectively. The protective impact of angiotensin converting enzyme (ACE)-inhibitor (ACE) intake has been suggested in other organ systems [13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Yahya

Ebert

Bulsara

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

Urinary symptoms (frequency, incontinence, dysuria and haematuria) were prospectively assessed using LENT-SOMA to a median of 72 months. The endpoints assessed were prevalence (grade≥1) at the end of radiotherapy (representing acute symptoms), at 18-, 36-and 54-month follow-ups (representing late symptoms) and peak late incidence including only grade≥2. Impact of factors were assessed using multivariate logistic regression models with correction for over-optimism. Results: Baseline symptoms, non-insulin dependent diabetes mellitus, age and PC1 (correlated to the mean dose) impact symptoms at >1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions:The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.4

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Yahya

Ebert

Bulsara

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…There is a growing trend of studying the relationships between treatment plan results and clinical outcomes, such as toxicities, survival, and patterns of failure [69][70][71][72][73][74][75][76][77]. Such studies may help physicians and physicists learn more about the influence of plan results and plan quality on patient treatment.…”

Section: Resultsmentioning

confidence: 99%

Physical and Radiobiological Evaluation of Radiotherapy Treatment Plan

Lee¹,

Cao²,

Kim³

2015

Evolution of Ionizing Radiation Research

View full text Add to dashboard Cite

Radiation treatment planning plays an important role in modern radiation therapy; it could simulate to plan the geometric, radiobiological, and dosimetric aspects of the therapy using radiation transport simulations and optimization. In this chapter, we have reviewed several quantitative methods used for evaluating radiation treatment plans and discussed some important considering points. For the purpose of quantitative plan evaluation, we reviewed dosimetrical indexes like PITV, CI, TCI, HI, MHI, CN, COSI, and QF. Furthermore, radiobiological indexes like Niemierko's EUD-based TCP and NTCP were included for the purpose of radiobiological outcome modeling. Additionally, we have reviewed dose tolerance for critical organs including RTOG clinical trial results, QUENTEC data, Emami data, and Milano clinical trial results. For the purpose of clinical evaluation of radiation-induced organ toxicity, we have reviewed RTOG and EORTC toxicity criteria. Several programs could help for the easy calculation and analysis of dosimetrical plan indexes and biological results. We have reviewed the recent trend in this field and proposed further clinical use of such programs. Along this line, we have proposed clinically optimized plan comparison protocols and indicated further directions of such studies.

show abstract

“…Disadvantages of the image guidance strategy directly focused on the organ are poor image quality (cone-beam computed tomography, ultrasound) and high costs (MRI). All this leads to the development of dose volume constraints to diminish the chance on rectal and urinary toxicity [13, 43]. …”

Section: Overview Of External Beam Radiation Treatmentsmentioning

confidence: 99%

Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Vanneste

Limbergen

Lin

et al. 2016

BioMed Research International

View full text Add to dashboard Cite

Radiotherapy (RT) for prostate cancer (PC) has steadily evolved over the last decades, with improving biochemical disease-free survival. Recently population based research also revealed an association between overall survival and doses ≥ 75.6 Gray (Gy) in men with intermediate- and high-risk PC. Examples of improved RT techniques are image-guided RT, intensity-modulated RT, volumetric modulated arc therapy, and stereotactic ablative body RT, which could facilitate further dose escalation. Brachytherapy is an internal form of RT that also developed substantially. New devices such as rectum spacers and balloons have been developed to spare rectal structures. Newer techniques like protons and carbon ions have the intrinsic characteristics maximising the dose on the tumour while minimising the effect on the surrounding healthy tissue, but clinical data are needed for confirmation in randomised phase III trials. Furthermore, it provides an overview of an important discussion issue in PC treatment between urologists and radiation oncologists: the comparison between radical prostatectomy and RT. Current literature reveals that all possible treatment modalities have the same cure rate, but a different toxicity pattern. We recommend proposing the possible different treatment modalities with their own advantages and side-effects to the individual patient. Clinicians and patients should make treatment decisions together (shared decision-making) while using patient decision aids.

show abstract

Relationships between bladder dose–volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer

Cited by 45 publications

References 25 publications

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Physical and Radiobiological Evaluation of Radiotherapy Treatment Plan

Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Contact Info

Product

Resources

About